Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Autor: Hoff FW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Blum WG; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Huang Y; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Welkie RL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Swords RT; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Traer E; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Stein EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lin TL; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS., Archer KJ; Division of Biostatistics, The Ohio State University, Columbus, OH., Patel PA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Collins RH; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Baer MR; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Duong VH; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Stock W; Department of Medicine, The University of Chicago, Chicago, IL., Odenike O; Department of Medicine, The University of Chicago, Chicago, IL., Redner RL; Department of Medicine, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA., Kovacsovics T; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Deininger MW; Department of Internal Medicine, Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI., Zeidner JF; Division of Hematology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Olin RL; Department of Medicine, University of California, San Francisco, San Francisco, CA., Smith CC; Department of Medicine, University of California, San Francisco, San Francisco, CA., Foran JM; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL., Schiller GJ; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA., Curran EK; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Koenig KL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Heerema NA; Department of Pathology, The Ohio State University, Columbus, OH., Chen T; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Martycz M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Stefanos M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Marcus SG; Leukemia & Lymphoma Society, Rye Brook, NY., Rosenberg L; Leukemia & Lymphoma Society, Rye Brook, NY., Druker BJ; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Levine RL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Burd A; Leukemia & Lymphoma Society, Rye Brook, NY., Yocum AO; Leukemia & Lymphoma Society, Rye Brook, NY., Borate UM; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Mims AS; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Byrd JC; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Madanat YF; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

Publikováno v: Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5297-5305.

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).

Autor: Ozga M; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Nicolet D; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA.; Alliance Statistics and Data Management Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Mrózek K; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. krzysztof.mrozek@osumc.edu.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA. krzysztof.mrozek@osumc.edu., Yilmaz AS; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA., Kohlschmidt J; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA.; Alliance Statistics and Data Management Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Larkin KT; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA., Blachly JS; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA., Oakes CC; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA., Buss J; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA., Walker CJ; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA., Orwick S; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Jurinovic V; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Rothenberg-Thurley M; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Dufour A; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Schneider S; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Institute of Human Genetics, University Hospital, LMU Munich, Munich, Germany., Sauerland MC; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany., Görlich D; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany., Krug U; Department of Medicine 3, Klinikum Leverkusen, Leverkusen, Germany., Berdel WE; Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany., Woermann BJ; German Society of Hematology and Oncology, Berlin, Germany., Hiddemann W; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Braess J; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany., Subklewe M; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Spiekermann K; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Carroll AJ; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA., Blum WG; Emory University School of Medicine, Atlanta, GA, USA., Powell BL; Wake Forest University Health Sciences, Winston-Salem, NC, USA., Kolitz JE; Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA., Moore JO; Duke Cancer Institute, Duke University Health System, Durham, NC, USA., Mayer RJ; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Larson RA; University of Chicago Medical Center, Chicago, IL, USA., Uy GL; Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA., Stock W; University of Chicago Medical Center, Chicago, IL, USA., Metzeler KH; Department of Hematology, Cellular Therapy, and Hemostaseology, Leipzig University Hospital, Leipzig, Germany., Grimes HL; Division of Immunobiology, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, USA.; Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA., Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA., Salomonis N; Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.; Division of Biomedical Informatics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, USA., Herold T; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Mims AS; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA., Eisfeld AK; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Ann.Kathrin.Eisfeld@osumc.edu.; The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA. Ann.Kathrin.Eisfeld@osumc.edu.

Publikováno v: Leukemia [Leukemia] 2024 Jan; Vol. 38 (1), pp. 45-57. Date of Electronic Publication: 2023 Nov 28.

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.

Autor: Raghunandan S; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA sraghu2@emory.edu.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Pauly M; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Blum WG; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Qayed M; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Dhodapkar MV; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Elkhalifa M; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Watkins B; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Schoettler M; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Horwitz E; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Parikh S; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Chandrakasan S; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Leung K; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Bryson E; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Deeb L; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Worthington-White D; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Alazraki A; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA., Schecter JM; Janssen Research and Development LLC, Raritan, New Jersey, USA., Madduri D; Janssen Research and Development LLC, Raritan, New Jersey, USA., Jackson CC; Janssen Research and Development LLC, Raritan, New Jersey, USA., Zudaire E; Janssen R&D, Spring House, Pennsylvania, USA., Taraseviciute-Morris A; Janssen Research and Development LLC, Raritan, New Jersey, USA., Babich A; Janssen R&D, Spring House, Pennsylvania, USA., Nesheiwat T; Legend Biotech USA Inc, Piscataway, New Jersey, USA., Vogel M; Janssen Global Services LLC, Raritan, New Jersey, USA., Lendvai N; Janssen Research and Development LLC, Raritan, New Jersey, USA., Pacaud L; Legend Biotech USA Inc, Piscataway, New Jersey, USA., Williams KM; Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 May; Vol. 11 (5).

Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.

Autor: Chen D; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Xia S; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Zhang R; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA., Li Y; Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Famulare CA; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Fan H; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA., Wu R; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA., Wang M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Zhu AC; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA., Elf SE; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA., Su R; Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA., Dong L; Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA., Arellano M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Blum WG; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Mao H; Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Lonial S; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA., Stock W; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA., Odenike O; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA., Le Beau M; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA., Boggon TJ; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA., He C; Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA., Chen J; Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA., Gao X; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA. Electronic address: xgao30@uchicago.edu., Levine RL; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: leviner@mskcc.org., Chen J; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA; Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA. Electronic address: jingchen@medicine.bsd.uchicago.edu.

Publikováno v: Molecular cell [Mol Cell] 2021 Sep 16; Vol. 81 (18), pp. 3833-3847.e11. Date of Electronic Publication: 2021 Jul 20.

Treating acute myeloid leukemia in the modern era: A primer.

Autor: Blum WG; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia., Mims AS; Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

Publikováno v: Cancer [Cancer] 2020 Nov 01; Vol. 126 (21), pp. 4668-4677. Date of Electronic Publication: 2020 Aug 07.